Having trouble accessing articles? Reset your cache.

A new lead in malaria

A consortium of researchers led by the Novartis Institute for Tropical Diseases has identified a potent new class of antimalarials that could provide a much needed safeguard against parasites resistant to the largely artemisinin-based armamentarium of malaria drugs. The consortium's experience suggests that directly screening in whole parasites-instead of first identifying a potential drug target-may be the most effective path to discovering new compounds.

Novartis AG hopes to begin a Phase I trial of the lead compound as early as year end.

In 2006, the World Health Organization (WHO) began recommending artemisinin-based combination therapies (ACTs) as first-line therapy for uncomplicated Plasmodium falciparum malarial infection. The move was a response to the spread of parasites resistant to chloroquine and sulphadoxine-pyrimethamine.1

Fixed-dose artemisinin

Read the full 1189 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers